Drug
Interferon Beta 1A
Interferon Beta 1A: highest development phase Post-Market, developed by Biogen, Merck. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Biogen, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Interferon-beta-1a NCT00492466 | Post-Market | Relapsing-Remitting Multiple Sclerosis |
| Interferon beta-1a NCT00574041 | Post-Market | Relapsing Remitting Multiple Sclerosis |
| Interferon beta-1a (Rebif) NCT01142466 | Post-Market | Multiple Sclerosis, Relapsing-Remitting |
Latest
No recent events.
Follow Interferon Beta 1A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.